Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Estrella Immunopharma activated Intermountain Health LDS Hospital in Salt Lake City as the fifth clinical site for its STARLIGHT-1 Phase I/II trial of EB103 in relapsed or refractory B-cell non-Hodgkin's lymphoma. The expansion phase is a multi-center, open-label study evaluating safety and efficacy of EB103 at the recommended Phase II dose, with data intended to inform a future pivotal trial strategy.
Key figures
- Drug Name
- EB103
- Phase Of Trial
- Phase I/II
- Nct id
- NCT06343311
- Trial name
- STARLIGHT-1
- Clinical site count
- 5
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.